Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy
| Autor: | Mona Olofsson, Jenny Hernestål Boman, Kurt Boman, Björn Dahlöf, Jonas Andersson |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Angiotensin receptor medicine.medical_specialty medicine.medical_treatment Adrenergic beta-Antagonists Left ventricular hypertrophy Losartan Muscle hypertrophy Renin-Angiotensin System Von Willebrand factor Double-Blind Method Internal medicine Fibrinolysis Plasminogen Activator Inhibitor 1 von Willebrand Factor medicine Humans Thrombophilia Aged biology business.industry Hematology General Medicine Middle Aged Atenolol medicine.disease Tissue Plasminogen Activator Hypertension biology.protein Cardiology Female Hypertrophy Left Ventricular business Plasminogen activator Angiotensin II Type 1 Receptor Blockers medicine.drug |
| Zdroj: | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 16(2) |
| ISSN: | 1938-2723 |
| Popis: | Objectives: To compare the effects of the β-blocker atenolol with the angiotensin receptor blocker (ARB) losartan on plasma tissue-type plasminogen activator (tPA) activity and mass concentration, plasminogen activator inhibitor-1 (PAI-1) activity, tPA/PAI-1 complex, and von Willebrand factor (VWF). Design: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy (LVH) performed within randomized multicenter, double-blind prospective study. Results: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass (11.9 vs 7.3 ng/mL, P = .019), PAI-1 activity (20.7 vs 4.8 IU/mL, P = .030), and tPA/PAI-1 complex (7.1 vs 2.5 ng/mL, P = .015). In patients treated with atenolol, median levels of tPA mass (8.9-11.9 ng/mL, P = .021) and VWF (113.5%-134.3%, P = .021) increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. Conclusion: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|